Clinical Antecedents of Adolescent-Onset MDD Identified

Share this content:
Clinical Antecedents of Adolescent-Onset MDD Identified
Clinical Antecedents of Adolescent-Onset MDD Identified

MONDAY, Dec. 12, 2016 (HealthDay News) -- Irritability and fear and/or anxiety are significant clinical antecedents of new adolescent-onset major depressive disorder (MDD) in individuals at familial risk, according to a study published online Dec. 7 in JAMA Psychiatry.

Frances Rice, Ph.D., from Cardiff University in the United Kingdom, and colleagues conducted a four-year longitudinal study to examine the developmental pathways that lead to first-episode adolescent-onset MDD among offspring of depressed parents. Participants included 337 families with an index parent who had experienced at least two episodes of MDD and who had a biologically-related child aged 9 to 17 years living with the index parent.

The researchers found that at follow-up, the offspring had a mean of 1.85 Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) symptoms of MDD. Twenty adolescents had new-onset MDD (mean age at onset, 14.4 years). Significant independent clinical antecedents of new adolescent-onset MDD included irritability and fear and/or anxiety, but not disruptive behavior and low mood. Similar results were seen for the DSM-IV symptom count at follow-up. All measured familial/genetic and social risk indicators influenced the risk of new-onset MDD directly, rather than through dimensional clinical antecedents.

"There are multiple pathways to first-onset adolescent depression in individuals at familial risk," the authors write. "Irritability and fear/anxiety may be additional clinical phenomena to be included as targets in primary preventive interventions focusing on the child."

Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »